Home › Companies › PLIANT THERAPEUTICS INC. › 2024-2025

PLIANT THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.

6Ballot items
147Asset managers
851Fund votes
June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 6 items on PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025: 3 approved · 3 without a stated outcome.

Material dissent

Elect Director: Katharine Knobil, M.D. 67% of votes cast Outcome not stated Director under 80%
Elect Director: Thomas McCourt 79% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PLIANT THERAPEUTICS INC.

These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PLIANT THERAPEUTICS INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: John Curnutte, M.D., Ph.D.	34,534,316	--	--	5,351,841	--	87%	Not verified	—
Elect Director: Katharine Knobil, M.D.	26,681,127	--	--	13,205,030	--	67%	Not verified	—
Elect Director: Thomas McCourt	31,557,399	--	--	8,328,758	--	79%	Not verified	—
2. On a non-binding advisory basis, the compensation of the Company's named executive officers	30,037,373	8,937,835	910,949	--	--	77%	Approved	—
Proposal 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law. The voting	35,232,687	3,771,806	881,664	--	--	90%	Approved	—
4. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025	50,796,112	506,011	931,004	--	--	99.0%	Approved	—

Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the PLIANT THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 147 asset managers that disclosed a PLIANT THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: John Curnutte, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 34,534,316WITHHELD: 5,351,841

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: John Curnutte, M.D., Ph.D.

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: John Curnutte, M.D., Ph.D.”): 34,534,316 for, 5,351,841 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 8,390,606 for, 539,836 withheld.

FOR

FOR: 8,390,606WITHHOLD: 539,836

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: John Curnutte, M.D.,” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,210,262	12,081	For
Charles Schwab	390,723	0	For
Dimensional	0	207,392	Withhold
TIAA	0	154,332	Withhold
Equitable	92,481	58,180	Mixed
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	34,937	44,809	Mixed
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	33,988	0	For
Global X	33,545	0	For
Pacific Life	29,030	0	For
T. Rowe Price	0	27,338	Withhold
Bridge Builder Trust	25,462	0	For
John Hancock	21,653	1,976	Mixed
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	18,363	0	For
Voya	16,319	0	For
JPMorgan	15,922	0	For
ProShares	14,009	0	For
SEI	11,200	0	For
Jackson National	0	9,535	Withhold
DWS	8,498	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

2. Elect Director: Katharine Knobil, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD

FOR: 26,681,127WITHHELD: 13,205,030

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: Katharine Knobil, M.D.

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Katharine Knobil, M.D.”): 26,681,127 for, 13,205,030 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 5,080,801 for, 3,849,641 withheld.

FORWITHHOLD

FOR: 5,080,801WITHHOLD: 3,849,641

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: Katharine Knobil, M.” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	3,365,967	0	For
BlackRock	0	2,854,683	Withhold
Fidelity	1,188,301	34,042	For
Charles Schwab	390,723	0	For
Dimensional	0	207,392	Withhold
TIAA	0	154,332	Withhold
Equitable	0	150,661	Withhold
QUANTITATIVE MASTER SERIES LLC	0	94,130	Withhold
Lincoln Financial	42,300	37,446	Mixed
Invesco	0	36,203	Withhold
Northern Trust	0	35,294	Withhold
AIG/SunAmerica	0	33,988	Withhold
Global X	33,545	0	For
Pacific Life	0	29,030	Withhold
T. Rowe Price	0	27,338	Withhold
Bridge Builder Trust	0	25,462	Withhold
John Hancock	0	23,629	Withhold
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	0	18,363	Withhold
Voya	0	16,319	Withhold
JPMorgan	15,922	0	For
ProShares	0	14,009	Withhold
SEI	11,200	0	For
Jackson National	0	9,535	Withhold
DWS	0	8,498	Withhold

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

3. Elect Director: Thomas McCourt

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD

FOR: 31,557,399WITHHELD: 8,328,758

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: Thomas McCourt

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas McCourt”): 31,557,399 for, 8,328,758 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 7,895,409 for, 1,035,033 withheld.

FOR

FOR: 7,895,409WITHHOLD: 1,035,033

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: Thomas McCourt” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,210,262	12,081	For
Charles Schwab	0	390,723	Withhold
Dimensional	0	207,392	Withhold
TIAA	0	154,332	Withhold
Equitable	92,481	58,180	Mixed
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	42,300	37,446	Mixed
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	0	33,988	Withhold
Global X	33,545	0	For
Pacific Life	29,030	0	For
T. Rowe Price	0	27,338	Withhold
Bridge Builder Trust	25,462	0	For
John Hancock	0	23,629	Withhold
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	0	18,363	Withhold
Voya	16,319	0	For
JPMorgan	15,922	0	For
ProShares	0	14,009	Withhold
SEI	11,200	0	For
Jackson National	0	9,535	Withhold
DWS	0	8,498	Withhold

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. Proposal 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

90% Approved · of votes cast

FOR 90%

FOR: 35,232,687AGAINST: 3,771,806

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF PLIANT THERAPEUTICS, INC. AS PERMITTED BY DELAWARE LAW.

PLIANT THERAPEUTICS INC.’s own tally for this item (“Proposal 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company a”): 35,232,687 for, 3,771,806 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 8,846,038 for, 84,404 against.

FOR

FOR: 8,846,038AGAINST: 84,404

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF CER” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,222,343	0	For
Charles Schwab	390,723	0	For
Dimensional	207,392	0	For
TIAA	154,332	0	For
Equitable	150,661	0	For
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	79,746	0	For
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	33,988	0	For
Global X	0	33,545	Against
Pacific Life	29,030	0	For
T. Rowe Price	27,338	0	For
Bridge Builder Trust	25,462	0	For
John Hancock	23,629	0	For
CLEARWATER INVESTMENT TRUST	0	19,488	Against
Goldman Sachs	18,363	0	For
Voya	16,319	0	For
JPMorgan	0	15,922	Against
ProShares	14,009	0	For
SEI	0	11,200	Against
Jackson National	9,535	0	For
DWS	8,498	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. 2. On a non-binding advisory basis, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

77% Approved · of votes cast

FOR 77%AGAINST

FOR: 30,037,373AGAINST: 8,937,835

Details: description as filed, official tally, votes by 147 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.

PLIANT THERAPEUTICS INC.’s own tally for this item (“2. On a non-binding advisory basis, the compensation of the Company's named executive officers”): 30,037,373 for, 8,937,835 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2: The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 39 asset managers voting on “To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,222,343	0	For
Charles Schwab	0	390,723	Against
Dimensional	0	207,392	Against
TIAA	0	154,332	Against
Equitable	92,481	58,180	Mixed
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	42,300	37,446	Mixed
Invesco	0	36,203	Against
Northern Trust	35,294	0	For
AIG/SunAmerica	0	33,988	Against
Global X	0	33,545	Against
Pacific Life	29,030	0	For
T. Rowe Price	0	27,338	Against
Bridge Builder Trust	25,462	0	For
John Hancock	0	23,629	Against
CLEARWATER INVESTMENT TRUST	0	19,488	Against
Goldman Sachs	0	18,363	Against
Voya	0	16,319	Against
JPMorgan	15,922	0	For
ProShares	0	14,009	Against
SEI	0	11,200	Against
Jackson National	0	9,535	Against
DWS	0	8,498	Against

Fund voting reports, all 39 managers: 7,786,486 for, 1,143,956 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 121 asset managers voting on “To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Deep Track Capital, LP	5,399,681	0	0	For
Blue Owl Capital Holdings LP	2,964,337	0	0	For
Cormorant Asset Management, LP	2,367,310	0	0	For
Madison Avenue Partners, LP	0	2,215,765	0	Against
TRV GP IV, LLC	2,132,867	0	0	For
Woodline Partners LP	2,030,963	0	0	For
Redmile Group, LLC	1,927,988	0	0	For
BlackRock	1,907,627	880	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,336,128	0	0	For
BESSEMER TRUST Co NATIONAL ASSOCIATION	0	1,059,466	0	Against
State Street	971,288	22,632	0	For
GREAT POINT PARTNERS LLC	0	0	850,000	Abstain
Bessemer Trust CO of Delaware, N.A.	0	536,888	0	Against
BESSEMER TRUST CO	0	532,118	0	Against
BESSEMER TRUST Co OF FLORIDA	0	532,118	0	Against
Bessemer Trust Co of Nevada, National Association	0	532,118	0	Against
Charles Schwab	0	390,723	0	Against
Rock Springs Capital Management LP	0	346,703	0	Against
ArrowMark Colorado Holdings LLC	0	281,189	0	Against
Northern Trust	253,903	4,991	0	For
Graham Capital Management, L.P.	0	231,343	0	Against
MELLON INVESTMENTS Corp	208,147	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	190,094	0	Against
Vanguard	160,596	23,162	0	Mixed
Nuveen	0	156,004	0	Against

Institutional-manager reports, all 121 managers: 21,905,274 for, 8,674,353 against, 850,000 abstained, 4,500 not voted. Showing the 25 largest; see all in the interactive database.

6. 4. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

99.0% Approved · of votes cast

FOR 99.0%

FOR: 50,796,112AGAINST: 506,011

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

PLIANT THERAPEUTICS INC.’s own tally for this item (“4. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 50,796,112 for, 506,011 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 4: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 39 asset managers below reported 8,930,208 for, 234 against.

FOR

FOR: 8,930,208AGAINST: 234

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,365,967	For
BlackRock	2,854,683	For
Fidelity	1,222,343	For
Charles Schwab	390,723	For
Dimensional	207,392	For
TIAA	154,332	For
Equitable	150,661	For
QUANTITATIVE MASTER SERIES LLC	94,130	For
Lincoln Financial	79,746	For
Invesco	36,203	For
Northern Trust	35,294	For
AIG/SunAmerica	33,988	For
Global X	33,545	For
Pacific Life	29,030	For
T. Rowe Price	27,338	For
Bridge Builder Trust	25,462	For
John Hancock	23,629	For
CLEARWATER INVESTMENT TRUST	19,488	For
Goldman Sachs	18,363	For
Voya	16,319	For
JPMorgan	15,922	For
ProShares	14,009	For
SEI	11,200	For
Jackson National	9,535	For
DWS	8,498	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

Largest PLIANT THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,386,278 shares outstanding at the time of that meeting.

Fund voting reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the resolution approving Named Executive Officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	5.48%
2	BlackRock	4.65%
3	Fidelity	1.99%
4	Charles Schwab	0.64%
5	Dimensional	0.34%
6	TIAA	0.25%
7	Equitable	0.25%
8	QUANTITATIVE MASTER SERIES LLC	0.15%
9	Lincoln Financial	0.13%
10	Invesco	0.06%

Institutional-manager reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the resolution approving Named Executive Officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	8.80%
2	Blue Owl Capital Holdings LP	4.83%
3	Cormorant Asset Management, LP	3.86%
4	Madison Avenue Partners, LP	3.61%
5	TRV GP IV, LLC	3.47%
6	Woodline Partners LP	3.31%
7	Redmile Group, LLC	3.14%
8	BlackRock	3.11%
9	GEODE CAPITAL MANAGEMENT, LLC	2.18%
10	BESSEMER TRUST Co NATIONAL ASSOCIATION	1.73%

Reported PLIANT THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PLIANT THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Tang Capital Management LLC	9.54%	DEF14A
Deep Track Capital, LP	9.37%	DEF14A
BlackRock	8.54%	13F
Vanguard Group	5.43%	13F
Paradigm Biocapital Advisors LP	4.98%	DEF14A
Morgan Stanley	4.97%	13F
Kenneth Griffin	4.96%	13G
Redmile Group, LLC	4.72%	13G
Bernard Coulie, M.D., Ph.D., M.B.A.	3.31%	DEF14A
Woodline Partners LP	3.30%	13G

Percentages above are of 61,386,278 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated May 1, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated May 1, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At PLIANT THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 147 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 851 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the resolution approving Named Executive Officers… — PLIANT THERAPEUTICS INC.'s filing reports the proposal as approved, with 77% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Download data (CSV): ballot items · votes by manager · column guide.